Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Path HoldingsBPTH +10.00% 3-1 Month Momentum % is -44.96% as of Jul. 29, 2026. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, Bio-Path Holdings ranks worse than 90.99% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Bio-Path Holdings's 3-1 Month Momentum % is -44.96%.
The industry rank for Bio-Path Holdings's 3-1 Month Momentum % or its related term are showing as below:
BPTH's 3-1 Month Momentum % is ranked worse than 90.99% of 1387
companies
in the Biotechnology industry
Industry Median: -10.62
vs BPTH: -44.96
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bio-Path Holdings 3-1 Month Momentum % Related Terms
BPTH vs AZTR, CLDI, BBLG: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Bio-Path Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a 3-1 Month Momentum % of -44.96% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #1262 out of 1387 companies in the Biotechnology industry, placing it in the top 91%.
Is Bio-Path Holdings' 3-1 Month Momentum % too high?
Bio-Path Holdings' current 3-1 Month Momentum % is -44.96%. Based on the distribution chart, Bio-Path Holdings ranks #1262 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' 3-1 Month Momentum % compare to AZTR and CLDI?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #1262 out of 1387 companies for 3-1 Month Momentum %. This places Bio-Path Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current 3-1 Month Momentum % is -44.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current 3-1 Month Momentum % of -44.96%. The current 3-1 Month Momentum % is -44.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current 3-1 Month Momentum % is -44.96% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 
